RPG Life Sciences Ltd (RPGLIFE)
₹2,575.70
Mkt cap
₹4,260 Cr
P/E ratio
37.10
P/B
6.19
Div yield
0.93%
ROE
19.30%
ROCE
25.70%
EPS (TTM)
₹69.43
Book value
₹416
52W range
1,733–3,128
Sector
Healthcare
Price history
Previous close
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients [1]
NSE RPGLIFEBSE 532983
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−17.65% from high₹2,576
₹1,733+48.63% from low₹3,128
Current
₹2,575.70
Prev close
₹3,003.80
Day
−14.25%
Price performance
1D
−15.27%
1W
−2.85%
1M
−17.62%
3M
−8.39%
6M
+25.34%
1Y
+8.52%
YTD
+11.38%
Financials
Revenue, profit & margin
P/E ratio
37.1×
RPGLIFE is 8% above the sector median of 34.4×
RPGLIFE37.1×
Sector median34.4×
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 173 | 143 | 169 | 182 | 180 | 177 | 196 | 212 | |
| Expenses | 124 | 118 | 133 | 143 | 140 | 144 | 152 | 171 | |
| Operating Profit | 49 | 25 | 35 | 39 | 40 | 33 | 44 | 40 | |
| OPM % | 28% | 18% | 21% | 21% | 22% | 19% | 22% | 19% | |
| Other Income | 3 | 115 | 5 | 16 | -5 | 14 | 4 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 7 | |
| Profit before tax | 47 | 135 | 35 | 49 | 29 | 40 | 41 | 37 | |
| Tax % | 26% | 13% | 26% | 25% | 24% | 26% | 26% | 24% | |
| Net Profit | 35 | 117 | 26 | 37 | 22 | 30 | 31 | 28 | |
| EPS in Rs | 21.12 | 70.95 | 15.90 | 22.28 | 13.38 | 18.08 | 18.49 | 16.08 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202672.95%Promoter
Promoters72.95%
FIIs0.87%0.08
DIIs9.93%1.25
Public16.24%1.18
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| RPG LifeScience. | ₹2,575.70 | 37.11 | 4,260 | 0.93% | 28 | −6.63% | 212 | +16.49% | 25.71% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts51
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Oct - Audio recording of Q2 FY27 earnings call made available online on October 30, 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 29 OctFinancial Results For The Quarter Ended September 30, 2026 29 Oct - Board approved unaudited standalone and consolidated results for quarter and half-year ended September 30, 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 29 Oct - Q2 FY27 revenue rose 16.5% to ₹211.6 crore; RPG Active Pharma acquired two API plants.Amendment To Policy 29 Oct - Board approved unaudited standalone and consolidated Q2 and half-year results on October 29, 2026.